Tsefou, E; Walker, AS; Clark, EH; Hicks, AR; Luft, C; Takeda, K; Watanabe, T; ... Ketteler, R; + view all Tsefou, E; Walker, AS; Clark, EH; Hicks, AR; Luft, C; Takeda, K; Watanabe, T; Ramazio, B; Staddon, JM; Briston, T; Ketteler, R; - view fewer (2021) Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches. Biochemical Journal , 478 (23) pp. 4099-4118. 10.1042/BCJ20210508.

Preview

Text Ketteler_DownloadCombinedArticleAndSupplmentPdf.pdf - Published Version Download (4MB) | Preview

Abstract

Mitochondrial dysfunction is implicated in Parkinson disease (PD). Mutations in Parkin, an E3 ubiquitin ligase, can cause juvenile-onset Parkinsonism probably through impairment of mitophagy. Inhibition of the de-ubiquitinating enzyme USP30 may counter this effect to enhance mitophagy. Using different tools and cellular approaches, we wanted to independently confirm this claimed role for USP30. Pharmacological characterization of additional tool compounds that selectively inhibit USP30 are reported. The consequence of USP30 inhibition by these compounds, siRNA knockdown and overexpression of dominant-negative USP30 in the mitophagy pathway in different disease-relevant cellular models was explored. Knockdown and inhibition of USP30 showed increased p-Ser65-ubiquitin levels and mitophagy in neuronal cell models. Furthermore, patient-derived fibroblasts carrying pathogenic mutations in Parkin showed reduced p-Ser65-ubiquitin levels compared to wild-type cells, levels that could be restored using either USP30 inhibitor or dominant-negative USP30 expression. Our data provide additional support for USP30 inhibition as a regulator of the mitophagy pathway.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as JSONXMLCSV

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item